Synopsis
Prevent stroke and invasive infection, prescribe antigen-matched transfusion for defined indications, detect alloimmunisation and iron loading, and recognise delayed haemolytic and hyperhaemolysis reactions.
- Functional hyposplenism makes encapsulated bacterial infection a lifelong risk; vaccination, antimicrobial prophylaxis and rapid empirical treatment are complementary layers, not substitutes.
- Children enter a transcranial Doppler programme because persistently abnormal cerebral arterial velocities identify a group that benefits from regular transfusion for primary stroke prevention.
- A new neurological deficit activates the hyperacute stroke pathway and urgent sickle transfusion discussion; a normal initial CT does not exclude ischaemic stroke.
- Transfusion indications include stroke prevention, severe acute chest syndrome and selected peri-operative or organ-threatening complications, not uncomplicated pain or steady-state anaemia alone.
- Before transfusion, retrieve the complete antibody history and use ABO-compatible, Rh- and Kell-matched, haemoglobin S-negative units with extended matching according to BSH guidance and individual antibodies.
- Genotyping is valuable when recent transfusion or variant Rh expression makes serological phenotype unreliable, and the result should be shared across transfusion networks.
- Simple transfusion raises haemoglobin but adds viscosity and iron; exchange lowers haemoglobin S while limiting net iron and can suit severe or long-term indications.
- Delayed haemolytic reaction may appear days to weeks later with pain, jaundice, dark urine and falling haemoglobin; a current antibody screen can be negative.
- Hyperhaemolysis destroys transfused and autologous cells, sometimes lowering haemoglobin below baseline; avoid reflex further transfusion while specialist immune treatment is organised.
- Chronic programmes require ferritin trends, liver iron MRI where indicated, chelation adherence review, vascular-access planning and repeated consent around burden and alternatives.
Key red flags
Haemoglobin below the pre-transfusion baseline with haemolysis and reticulocyte suppression or rise requires urgent specialist management before more blood.
Investigation priorities
Stratify primary stroke risk in children with sickle-cell anaemia.
Management branches
Sickle-cell disease is diagnosed or a first planned transfusion approaches.
- Obtain extended antigen phenotype or genotype before transfusion where possible and retrieve records from every previous transfusion provider.
- Record all current and historical alloantibodies and issue a patient-held transfusion alert linked to the haemoglobinopathy network.
- Request BSH-standard sickle-compatible antigen matching and select simple or exchange technique from indication, baseline haemoglobin, urgency and iron burden.
Routine review, travel planning or a change in vaccine or prophylaxis status occurs.
- Reconcile national routine and functional-asplenia vaccines, annual influenza and travel requirements with primary care and the specialist service.
- Prescribe indicated penicillin prophylaxis with an allergy alternative and address adherence barriers without implying that tablets replace vaccines.
- Give explicit instructions and access routes for immediate assessment of fever or systemic illness, including when away from the home hospital.
Key medicines
PhenoxymethylpenicillinFollow the current sickle and asplenia protocol, commonly 250 mg orally twice daily in adults for ongoing prophylaxis, with macrolide or other local alternative for genuine allergy.Breakthrough sepsis remains possible; check adherence, allergy accuracy and local resistance advice and ensure fever triggers immediate hospital treatment rather than extra prophylactic doses.
DeferasiroxFor transfusional overload, a common film-coated-tablet starting dose is 14 mg/kg orally once daily; adjust in 3.5–7 mg/kg steps to transfusion rate, ferritin trend and MRI tissue iron. Dispersible tablets use different strengths and must not be interchanged dose for dose.Check creatinine and eGFR in duplicate before treatment and monitor renal, urinary protein and liver indices closely; gastrointestinal bleeding, cytopenia and dehydration-related kidney injury require interruption or review. Avoid basing treatment on one inflammatory ferritin.